😀

Finally, I don’t see an advantage in leaving RE sites in. When you recombine fragments to test out new variants you need to start again with the PCR fragments flanked by RE sites, whether the latter will stay in the genome or not its the same procedure
3/

Thirdly, the RE sites Bruttel et al sell as engineering footprints are neither at gene borders nor regularly spaced (even an 800 nt fragment D in the ORF1b) - makes no sense
2/

Firstly, I did not allow @mbweissman.bsky.social to publish my private response to him. This is a breach of confidentiality. I have reported it

Secondly, engineering RE sites into a virus genome could jeopardize functionality, so why would anyone do that with a novel, unknown genome?
1/

Das verstößt aber gegen das Weber-Fechnersche Gesetz

Teile der Antwort könnten die Bevölkerung verstören